Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor

Molecular Cytogenetics

Alfredo Corona-Rivera³  Oscar González-Ramella⁵  Abraham Zepeda-Moreno²  Jorge R Corona-Rivera¹  Rocio Silva-Cruz¹  Fernando Sánchez-Zubieta⁵  Citlalli Ortega-de-la-Torre¹  Jenny A Paniagua-Padilla⁵  Sergio Gallegos-Castorena⁵  Helia J Pimentel-Gutiérrez⁴  Lucina Bobadilla-Morales¹ 

[1] División de Pediatría, Centro de Registro e Investigación sobre Anomalías Congénitas (CRIAC), Nuevo Hospital Civil de Guadalajara, “Dr. Juan I. Menchaca”, Guadalajara, Jalisco, México;Instituto de Investigación en Cáncer de la Infancia y la Adolescencia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México;Laboratorio de Citogenética Genotoxicidad y Biomonitoreo, Instituto de Genética Humana “Dr. Enrique Corona-Rivera”, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, #Sierra Mojada 950, S.L., Edificio P, Nivel 2, Col. Independencia, Guadalajara CP: 44340, Jalisco, México;Unidad de Citogenética, Servicio de Hematología y Oncología Pediátrica, División de Pediatría, Nuevo Hospital Civil de Guadalajara, “Dr. Juan I. Menchaca”, Guadalajara, Jalisco, México;Servicio de Hematología y Oncología Pediátrica, División de Pediatría, Nuevo Hospital Civil de Guadalajara, “Dr. Juan I. Menchaca”, Guadalajara, Jalisco, México

关键词: Donor cell leukemia;    Acute myeloid leukemia;    Allogeneic hematopoietic stem cell transplantation;   

Others  :  1132195
DOI  :  10.1186/s13039-014-0105-4

 received in 2014-09-19, accepted in 2014-12-26,  发布年份 2015

【 摘 要 】

Here we present a male patient with acute myeloid leukemia (AML) initially diagnosed as M5 and with karyotype 46,XY. After induction therapy, he underwent a HLA-matched allogeneic hematopoietic stem cell transplantation, and six years later he relapsed as AML M1 with an abnormal karyotype //47,XX,+10[2]/47,XX,+11[3]/48,XX,+10,+11[2]/46,XX[13]. Based on this, we tested the possibility of donor cell origin by FISH and molecular STR analysis. We found no evidence of Y chromosome presence by FISH and STR analysis consistent with the success of the allogeneic hematopoietic stem cell transplantation from the female donor. FISH studies confirmed trisomies and no evidence of MLL translocation either p53 or ATM deletion. Additionally 28 fusion common leukemia transcripts were evaluated by multiplex reverse transcriptase-polymerase chain reaction assay and were not rearranged. STR analysis showed a complete donor chimerism. Thus, donor cell leukemia (DCL) was concluded, being essential the use of cytological and molecular approaches. Pediatric DCL is uncommon, our patient seems to be the sixth case and additionally it presented a late donor cell leukemia appearance. Different extrinsic and intrinsic mechanisms have been considered to explain this uncommon finding as well as the implications to the patient.

【 授权许可】

   
2015 Bobadilla-Morales et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Alseraye FM, Zuo Z, Bueso-Ramos C, Wang S, Medeiros LJ, Lu G: Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation. Int J Clin Exp Pathol 2011, 4:371-7.
• [2]Pui CH, Carroll WL, Meshinchi S, Arceci RJ: Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-65.
• [3]Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, et al.: NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. Biol Blood Marrow Transplant 2010, 16:871-90.
• [4]Cho BS, Kim HJ, Eom KS, Lee JW, Min WS, Kim CC: A case report of the second de novo acute myeloid leukemia (AML) following allogeneic stem cell transplantation in a patient with the first AML. Korean J Intern Med 2010, 25:110-3.
• [5]Reichard K, Zhang QY, Sanchez L, Hozier J, Viswanatha D, Foucar K: Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: case report and review of the literature. Am J Hematol 2006, 81:178-85.
• [6]Wiseman DH: Donor cell leukemia: a review. Biol Blood Marrow Transplant 2011, 17:771-89.
• [7]Wang E, Hutchinson CB, Huang Q, Lu CM, Crow J, Wang FF, et al.: Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature. Am J Clin Pathol 2011, 135:525-40.
• [8]Flynn CM, Kaufman DS: Donor cell leukemia: insight into cancer stem cells and the stem cell niche. Blood 2007, 109:2688-92.
• [9]Fraser CJ, Hirsch BA, Dayton V, Creer MH, Neglia JP, Wagner JE, et al.: First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. Blood 2005, 106:4377-80.
• [10]Otero L, de Souza DC, de Cassia TR, Gomes BE, Padilha TF, Bouzas LF, et al.: Monosomy 7 in donor cell-derived leukemia after bone marrow transplantation for severe aplastic anemia: Report of a new case and review of the literature. Genet Mol Biol 2012, 35:734-6.
• [11]Yuan J, McDonough C, Kulharya A, Ramalingam P, Manaloor E: Isolated trisomy 10 in an infant with acute myeloid leukemia: a case report and review of literature. Int J Clin Exp Pathol 2010, 3:718-22.
• [12]Suzuki A, Kimura Y, Ohyashiki K, Kitano K, Kageyama S, Kasai M, et al.: Trisomy 10 in acute myeloid leukemia. Three additional cases from the database of the Japan Adult Leukemia Study Group (JALSG) AML-92 and AML-95. Cancer Genet Cytogenet 2000, 120:141-3.
• [13]Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, et al.: ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012, 26:265-70.
• [14]Leone G, Pagano L, Ben-Yehuda D, Voso M: Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92:1389-98.
• [15]Godley L, Larson R: Therapy-related myeloid leukemia. Semin Onco 2008, 35:418-29.
• [16]Larson R: Therapy-related myeloid neoplasms. Haematologica 2009, 94:454-9.
• [17]Goh K, Klemper MR: In vivo leukemic transformation: cytogenetic evidence of in vivo leukemic transformation of engrafted marrow cells. Am J Hematol 1977, 2:283-90.
• [18]Smith JL, Heerema NA, Provisor AJ: Leukaemic transformation of engrafted bone marrow cells. Br J Haematol 1985, 60:415-22.
• [19]Feig SA, Dreazen O, Simon M, Wiley F, Schreck F, Gale RP: B cell acute lymphoblastic leukemia (ALL) in donor cells following bone marrow transplantation for T cell ALL. Bone Marrow Transplant 1988, 3(4):331-7.
• [20]Mouratidou M, Sotiropoulous D, Deremitzaki K, Spathas DH, Hoffbrand AV, Prentice HG, et al.: Recurrence of acute leukemia in donor cells after bone marrow transplantation: documentation by in situ DNA hybridization. Bone Marrow Transplant 1993, 12:77-80.
• [21]Sala TO, Loeb KR: Donor cell-derived leukemia and myelodysplastic neoplasm: unique forms of leukemia. Am J Clin Pathol 2011, 135:501-4.
• [22]Wang H, Chen XQ, Geng QR, Liu PP, Lin GN, Xia ZJ, et al.: Induction therapy using the MRC UKALLXII/ECOG E2993 protocol in Chinese adults with acute lymphoblastic leukemia. Int J Hematol 2011, 94:163-8.
• [23]Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, et al.: Development of leukemia in donor cells after allogeneic stem cell transplantation–a survey of the European Group for Blood and Marrow Transplantation. Haematologica 2005, 90:969-75.
• [24]Kim YW, Koo BK, Jeong HW, Yoon MJ, Song R, Shin J, et al.: Defective Notch activation in microenvironment leads to myeloproliferative disease. Blood 2008, 112:4628-38.